Arenicin-1 vs Mazdutide
Head-to-head comparison of Arenicin-1 (Arenicin-1) and Mazdutide (IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Arenicin-1 | Mazdutide |
|---|---|---|
| Category | Marine-Derived | Weight Management |
| Full Name | Arenicin-1 | IBI362, long-acting GLP-1 receptor and glucagon receptor dual agonist |
| Molecular Weight | 2079 Da | ~5,000 Da |
| Half-Life | n/a | 5-7 days |
| Amino Acids | 21 | 37 |
| Typical Dose | n/a | 1-6 mg weekly in obesity trials |
| Route | preclinical | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 76 | 28 |
| Research Status | Pre-clinical | Clinical |
Arenicin-1 Benefits
- ✓antimicrobial
- ✓anti-biofilm
- ✓membrane-active
Mazdutide Benefits
- ✓clinically meaningful weight loss
- ✓better glycemic control
- ✓reduced waist circumference
- ✓improved lipid profile
Arenicin-1 Dosing
bacterial infection|biofilm disruption
Mazdutide Dosing
Once-weekly SC titration|Dose escalation every 4 weeks|Use with lifestyle modification
Arenicin-1 Side Effects
- ⚠Arenicola marina
Mazdutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠constipation
Research Overview
Arenicin-1
Marine annelid peptide with strong preclinical antibacterial activity and a stable structural motif that is useful for peptide engineering.
Mazdutide
Clinical programs have shown substantial reductions in body weight and improvements in cardiometabolic risk markers. It is a prominent newer dual agonist in the obesity literature.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.